RiteMED Telmisartan

Essential HTN. Reduction of risk of non-fatal stroke or MI in patients ≥55 yr at high risk of developing major CV events who cannot tolerate an ACE inhibitor.

Essential HTN 40 mg once daily, may be increased to max: 80 mg once daily. Severe HTN 160 mg alone & in combination w/ hydrochlorothiazide 12.5-25 mg daily. Reduction of CV morbidity 80 mg once daily. Mild to moderate hepatic impairment Not to exceed 40 mg once daily.

May be taken with or without food.

Hypersensitivity. Biliary obstructive disorders. Not to be taken by patients w/ fructose intolerance. Concomitant use w/ aliskiren in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m²). Severe hepatic impairment. 2nd & 3rd trimesters of pregnancy. Lactation.

Not recommended in primary aldosteronism. Patients w/ bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney; whose vascular tone & renal function depend predominantly on activity of renin-angiotensin-aldosterone system eg, severe CHF or underlying renal disease including renal artery stenosis; suffering from aortic or mitral valve stenosis, or obstructive hypertrophic cardiomyopathy; DM & coexistent CAD; ischaemic cardiopathy or CV disease. Correct vol &/or Na depletion prior to administration. Dual blockade of renin-angiotensin-aldosterone system (ie, by adding ACE inhibitor). Concomitant use w/ K-sparing diuretics, K supplements, K-containing salt substitutes or other medicinal products that may increase K level eg, heparin. Black patients. Periodic monitoring of K & creatinine serum levels in patients w/ renal impairment. Dizziness or drowsiness may occasionally occur which should be accounted when driving vehicles or operating machinery. Patients w/ biliary obstructive disorders or hepatic insufficiency. Not recommended during 1st trimester of pregnancy. Not recommended in childn <18 yr.

UTIs (including cystitis), URTIs, sepsis including fatal outcome; anaemia, eosinophilia, thrombocytopenia; anaphylactic reaction, hypersensitivity; hyperkalaemia, hypoglycaemia (in diabetic patients); insomnia, depression, anxiety; syncope; visual disturbance; vertigo; bradycardia, tachycardia; hypotension, orthostatic hypotension; dyspnoea; abdominal pains, diarrhoea, dyspepsia, flatulence, vomiting, dry mouth, stomach discomfort; abnormal hepatic function/liver disorder; pruritus, hyperhidrosis, rash, angioedema (w/ fatal outcome), eczema, erythema, urticaria, drug eruption, toxic skin eruption; back & tendon pain, muscle spasms, myalgia, arthralgia, pain in extremity; renal impairment including acute renal failure; chest pain, asthenia, flu-like illness; increased blood creatinine, hepatic enzymes, blood uric acid & blood creatine phosphokinase, decreased Hb.

May increase hypotensive effect of other antihypertensive agents. Increased median plasma trough conc of digoxin. Reversible increases in serum lithium conc & toxicity. Reduced antihypertensive effect w/ NSAIDs.

Angiotensin II Antagonists

C09CA07 - telmisartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

Rx